Charles Schwab
INMB icon

Charles Schwab’s INmune Bio INMB Stock Holding History

Charles Schwab’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.8K Hold
50,252
– – ﹤0.01% 3416
2025
Q4 		$78.4K Buy
50,252
+8,427
+20% +$15K ﹤0.01% 3408
2025
Q3 		$86.6K Sell
41,825
-10,000
-19% -$22.9K ﹤0.01% 3398
2025
Q2 		$120K Buy
51,825
+10,505
+25% +$77.1K ﹤0.01% 3408
2025
Q1 		$323K Buy
41,320
+6,654
+19% +$52.8K ﹤0.01% 3189
2024
Q4 		$162K Buy
34,666
+676
+2% +$3.52K ﹤0.01% 3348
2024
Q3 		$183K Sell
33,990
-3,285
-9% -$23.4K ﹤0.01% 3344
2024
Q2 		$329K Buy
+37,275
New +$367K ﹤0.01% 3340

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab's INMB Position: Q1 2026 in Review

Charles Schwab held its INmune Bio (INMB) position steady in Q1 2026 at 50,252 shares worth $56.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3416.

Charles Schwab first reported a position in INMB in Q2 2024 and has held it in 8 quarters since. The position peaked at $329K in Q2 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Charles Schwab held 50,252 shares of INmune Bio worth $56.8K as of Q1 2026.
  • Charles Schwab left its INmune Bio share count unchanged in Q1 2026.
  • INmune Bio made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #3416 holding.
  • Charles Schwab first reported a position in INmune Bio in Q2 2024 and has held it in 8 quarters since.
  • Charles Schwab's INmune Bio position peaked at $329K in Q2 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.